- Company
- Venclexta will be prescribed in major hospitals soon
- by Eo, Yun-Ho Mar 12, 2020 06:07am
- Venclaxta, which is ready for insurance benefits, will be prescribed at a general hospital soon. According to the related industry, Abbvie's Chronic Lymphocytic Leukemia (CLL) treatment, Venclexta (Venetoclax), passed DC (drug committee) of 5 big major Hospitals such as Seoul National University Hospital, Seoul St. Mary's Hospital, Severan
- Policy
- Probe that detects COVID-19 was successfully made
- by Kim, Jung-Ju Mar 12, 2020 06:07am
- While global attention is focused on the development of 'COVID-19' therapeutics, government-level development research is also in full swing. The government has succeeded in producing specific proteins to detect these infectious antibodies. The National Institute of Health (President Jun-Wook Kwon) in the KCDC (Director Eun-Kyung Jung) ann
- Company
- “No changes in safety and efficacy of montelukast”
- by Kim, Jin-Gu Mar 12, 2020 06:07am
- Medical academics argue there is “no change in safety and efficacy of montelukast,” currently controversial with safety risk. Director Kim Chang Geun of Inje Uniersity Sanggye Paik Hospital the Asthma and Allergies Center spoke on Mar. 9 at a roundtable with press. The President of Pneumonia and Respiratory Diseases Study Group at
- Policy
- Study for effects of Truvada and Kaletra will continue
- by Lee, Jeong-Hwan Mar 12, 2020 06:06am
- The government plans to continue research on the effectiveness of COVID-19 therapeutic substances and patient administration through various methods such as clinical trials. Following the clinical approval of Remdesivir, It will continue to study the necessity of administering drugs that are expected to be effective in treating corona, su
- Company
- Household brand pain reliever Geworin price goes up
- by Jung, Hye-Jin Mar 12, 2020 06:03am
- Household brand pain reliever Geworin’s price would be raised by 8 percent to 9 percent around March or April. According to pharmacy and pharmaceutical distributor sources, Samjin Pharm has decided to adjust supply price of Geworin after contemplating on it for months. In this week, the company would officially notify the decision to wh
- Policy
- Court suspends execution of Forsteo price reduction
- by Kim, Jung-Ju Mar 12, 2020 06:03am
- Price reduction of Lilly Korea’s osteoporosis treatment Forsteo (teriparatide) is temporarily deferred, although it was notified earlier to be executed this month. The company has reportedly filed a lawsuit to cancel the government-authorized price reduction. On Feb. 28, Seoul Administrative Court has granted suspension of execution
- Product
- CartiLife has passed 5 years follow-up result
- by choi. sun Mar 11, 2020 06:27am
- Domestic osteoarthritic treatment has shown positive results for bone repair in the long-term follow-up of five years. The results are encouraging, as the osteoarthritis treatments that have shown their intention to compete have failed to demonstrate 'Disease Modifying OestoArthritis Drugs' (DMOAD) that structurally inhibit disease progressio
- Company
- Next-gen insulin medications approved for pediatric patients
- by Eo, Yun-Ho Mar 11, 2020 06:27am
- Next generation insulin medications are actively seeking for expanded indication to treat children and adolescents. Novo Nordisk’s rapid-acting insulin Fiasp FlexTouch (insulin aspart) has recently won indication to treat to children aged under two and adolescents. Fiasp is a next-generation fast-acting mealtime insulin injection that
- Company
- Celltrion, apply for European license for CT-P17
- by An, Kyung-Jin Mar 11, 2020 06:27am
- Celltrion is the first in the Humira (Adalimumab) market for its global sales of &8361;20 billion. Celltrion announced on the 9th that it has completed application for Humira biosimilar 'CT-P17' to the European Medicines Agency (EMA) on the 6th (local time). Humira, the original drug of CT-P17, is the most sold blockbuster product in t
- Company
- Drug industry's ‘Corona Blue,’ “We miss our mundane life"
- by Chon, Seung-Hyun Mar 11, 2020 06:27am
- 50 days have passed since the 2019 novel coronavirus (COVID-19) started infecting Korea. COVID-19 has consumed the whole of Korea in merely 20 days after 31st patient was confirmed with infection on last Feb. 19. As of last Sunday 4 p.m., 7,313 people were confirmed with COVID-19 in Korea. As the COVID-19 outbreak has been lingering l
